Picture EBD Group Global Partnering Four Events One Price 650x80
Document › Details

Autolus Ltd.. (4/4/18). "Press Release: Autolus and Miltenyi Biotec Sign Strategic Supply Agreement". London.

Organisation Organisation Autolus Therapeutics Ltd.
  Today Autolus Therapeutics plc (Nasdaq: AUTL)
  Group Autolus Therapeutics plc (Nasdaq: AUTL)
Products Product CliniMACS Prodigy® platform
  Product 2 T cell therapy
Index term Index term Autolus–Miltenyi Biotec: cell therapy manufacturing technology, 201804– supply long-term CliniMACS Prodigy systems + consumables for T cell mftg
Persons Person Itin, Christian (Autolus 201603– CEO before Cytos 201211–201601 + Micromet 1999–2012 CEO + Co-founder + Zyomyx Inc)
  Person 2 Miltenyi, Stefan (Miltenyi Biotec 201404 Founder + President)

- Agreement covers supply and support of Miltenyi Biotec Prodigy® platform for the manufacture of Autolus programmed T cell therapies -

Autolus Limited (“Autolus”), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, and Miltenyi Biotec GmbH (“Miltenyi Biotec”), a global provider of products and services that advance biomedical research and cellular therapy, today announced that they have signed a strategic, long-term supply agreement on the supply and support of Miltenyi Biotec’s CliniMACS Prodigy® instruments, reagents and disposables for the manufacture of Autolus’ programmed T cell therapies.

Utilising the state-of-the-art, automated cell processing platform CliniMACS Prodigy®, Autolus has established a GMP production process for its programmed T cell therapies designed to address the challenges of commercial-scale manufacturing. Parallel processing of a large number of patient samples in closed systems is key to achieving economic, scalable and reliable commercial manufacture of T cell therapies.

Dr Christian Itin, CEO of Autolus, said: “We are delighted to announce our strategic relationship with Miltenyi Biotec, a pioneer in design and engineering of equipment and reagents that support production of cell therapies. This agreement builds on the longstanding collaboration between our companies and leverages our respective leadership positions in programmed T cell therapies, process design, engineering and automation.”

Stefan Miltenyi, President and CEO at Miltenyi Biotec, added: “Autolus is a leader in the development of programmed T cell therapies. We are, therefore, delighted that Autolus has chosen our Prodigy platform for the manufacture of its clinical-stage portfolio and we look forward to further demonstrating its utility in the commercial manufacture of advanced T cell therapies.”

– Ends –

Media Contacts:

JW Communications
Julia Wilson
+44 (0)7818 430877

Miltenyi Biotec Media Contact
Holger Buelow
+49 2204 8306-6680

About Autolus

Autolus is a private, clinical-stage, biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognise cancer cells, break down their defence mechanisms and attack and kill these cells.

Autolus has a pipeline of products in development for the treatment of both haematological malignancies and solid tumours. For further information, please visit the company’s website at:

About Miltenyi Biotec

Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. The company is committed to enable commercial scale cell and gene therapy for the delivery of new treatment options to patients with unmet medical need. The company’s state-of-the-art technologies and products provide integrated workflows for research and clinical applications and have set a new industry standard in automated manufacturing of complex cellular products such as CAR T cells, TCR-transduced T cells, and gene-modified stem cells. Miltenyi Biotec’s portfolio of instruments, reagents and disposables is complemented with contract development and cGMP manufacturing services for lentiviral vectors and cellular products based on the company’s unique platforms for cell processing and cellular analytics. Miltenyi Biotec has more than 2,000 employees in 28 countries and its products have been used in more than 50,000 cell therapy procedures. For more information please visit

Record changed: 2018-10-18


Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Autolus Therapeutics plc (Nasdaq: AUTL)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Global Partnering Four Events One Price 650x80

» top